JP2014500243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500243A5 JP2014500243A5 JP2013535018A JP2013535018A JP2014500243A5 JP 2014500243 A5 JP2014500243 A5 JP 2014500243A5 JP 2013535018 A JP2013535018 A JP 2013535018A JP 2013535018 A JP2013535018 A JP 2013535018A JP 2014500243 A5 JP2014500243 A5 JP 2014500243A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 4
- 230000029142 excretion Effects 0.000 claims 4
- -1 -O- aralkyl Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000008604 lipoprotein metabolism Effects 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 206010024604 Lipoatrophy Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39413610P | 2010-10-18 | 2010-10-18 | |
| US61/394,136 | 2010-10-18 | ||
| US201161444212P | 2011-02-18 | 2011-02-18 | |
| US61/444,212 | 2011-02-18 | ||
| PCT/US2011/056780 WO2012054535A2 (en) | 2010-10-18 | 2011-10-18 | Compounds, compositions and methods useful for cholesterol mobilisation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015241010A Division JP6127120B2 (ja) | 2010-10-18 | 2015-12-10 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500243A JP2014500243A (ja) | 2014-01-09 |
| JP2014500243A5 true JP2014500243A5 (enExample) | 2014-12-04 |
| JP5856177B2 JP5856177B2 (ja) | 2016-02-09 |
Family
ID=45975848
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535018A Active JP5856177B2 (ja) | 2010-10-18 | 2011-10-18 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2015241010A Active JP6127120B2 (ja) | 2010-10-18 | 2015-12-10 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2016114435A Active JP6254222B2 (ja) | 2010-10-18 | 2016-06-08 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2017077272A Pending JP2017128602A (ja) | 2010-10-18 | 2017-04-10 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2017228551A Ceased JP2018058874A (ja) | 2010-10-18 | 2017-11-29 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015241010A Active JP6127120B2 (ja) | 2010-10-18 | 2015-12-10 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2016114435A Active JP6254222B2 (ja) | 2010-10-18 | 2016-06-08 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2017077272A Pending JP2017128602A (ja) | 2010-10-18 | 2017-04-10 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
| JP2017228551A Ceased JP2018058874A (ja) | 2010-10-18 | 2017-11-29 | コレステロールモビリゼーションに有用な化合物、組成物及び方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US8349833B2 (enExample) |
| EP (2) | EP3241833A1 (enExample) |
| JP (5) | JP5856177B2 (enExample) |
| KR (2) | KR20180014188A (enExample) |
| CN (3) | CN107011359A (enExample) |
| AU (1) | AU2011317152C1 (enExample) |
| BR (1) | BR112013009485A2 (enExample) |
| CA (1) | CA2813994A1 (enExample) |
| CY (1) | CY1119547T1 (enExample) |
| DK (1) | DK2629776T3 (enExample) |
| ES (1) | ES2646835T3 (enExample) |
| HR (1) | HRP20171587T1 (enExample) |
| HU (1) | HUE034637T2 (enExample) |
| IL (4) | IL225785A (enExample) |
| LT (1) | LT2629776T (enExample) |
| MX (1) | MX337179B (enExample) |
| NO (1) | NO2629776T3 (enExample) |
| NZ (6) | NZ705731A (enExample) |
| PH (4) | PH12013500480B1 (enExample) |
| PL (1) | PL2629776T3 (enExample) |
| PT (1) | PT2629776T (enExample) |
| RS (1) | RS56529B1 (enExample) |
| RU (1) | RU2576402C2 (enExample) |
| SG (4) | SG189019A1 (enExample) |
| SI (1) | SI2629776T1 (enExample) |
| SM (1) | SMT201700533T1 (enExample) |
| WO (1) | WO2012054535A2 (enExample) |
| ZA (2) | ZA201301827B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171587T1 (hr) * | 2010-10-18 | 2017-12-01 | Cerenis Therapeutics Holding Sa | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| CA2903979A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| US9732065B2 (en) | 2013-05-30 | 2017-08-15 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic aminomethyl pyrimidine derivative |
| WO2018067431A1 (en) * | 2016-10-03 | 2018-04-12 | Purdue Research Foundation | Re-sensitizing drug-resistant cancer cells by combinational therapy |
| US20200054651A1 (en) * | 2017-02-03 | 2020-02-20 | The Regents Of The University Of California | Compositions and methods for modulating ppp2r1a |
| SG11202010914YA (en) | 2018-05-11 | 2020-12-30 | Glaxosmithkline Ip Dev Ltd | Furin inhibitors |
| CN108815177A (zh) * | 2018-06-08 | 2018-11-16 | 华东师范大学 | P2y13激动剂在抗病毒感染中的应用 |
| EP4003314B1 (en) | 2019-07-26 | 2024-07-10 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
| IT202000006517A1 (it) | 2020-03-27 | 2021-09-27 | Istituto Naz Fisica Nucleare | Small molecules che inducono la degradazione della proteina prionica cellulare |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| CN114853664B (zh) * | 2022-06-02 | 2023-09-29 | 河南大学 | 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| JPS4911710B1 (enExample) * | 1970-12-30 | 1974-03-19 | ||
| JPS4911710A (enExample) | 1972-05-15 | 1974-02-01 | ||
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3939159A (en) * | 1974-05-29 | 1976-02-17 | American Hoechst Corporation | Spiro(pyrrolo (1,2-A)quinoxalines) |
| US3935222A (en) * | 1975-04-16 | 1976-01-27 | E. R. Squibb & Sons, Inc. | 1,4,5,7-Tetrahydropyrazolo[3,4-b]pyridin-6-ones |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| CA1147658A (en) * | 1980-01-03 | 1983-06-07 | Edouard Panak | Therapeutic compositions having antithrombotic and anti-blood-platelet- aggregating activity |
| FR2495156A1 (fr) | 1980-11-28 | 1982-06-04 | Sanofi Sa | Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique |
| FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| JPH0559081A (ja) | 1991-08-29 | 1993-03-09 | Kirin Brewery Co Ltd | 新規スフインゴ糖脂質、その製造法および使用 |
| FI101150B (fi) | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB9309573D0 (en) | 1993-05-10 | 1993-06-23 | Merck Sharp & Dohme | Therapeutic agents |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| AR048564A1 (es) * | 1996-12-05 | 2006-05-10 | Amgen Inc | Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8 |
| US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| EP1053243B1 (en) | 1998-02-12 | 2011-03-30 | Emory University | Sphingolipid derivatives and their methods of use |
| WO2000039103A1 (en) * | 1998-12-23 | 2000-07-06 | Aventis Pharma Limited | Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines |
| JP3989247B2 (ja) * | 1999-12-06 | 2007-10-10 | ユーロ−セルティーク エス．エイ． | ノシセプチン受容体親和性を有するトリアゾスピロ化合物 |
| AU2006201262B2 (en) * | 2000-09-15 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Pyrazole Compounds Useful As Protein Kinase Inhibitors |
| WO2003095427A1 (en) | 2002-05-10 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Spiro-ring compound |
| DK2316831T3 (da) | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
| WO2005076007A2 (en) * | 2004-02-03 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12) |
| EP1604669A1 (en) * | 2004-06-10 | 2005-12-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of ATP analogues for treatment of cardiovascular diseases |
| CA2654608A1 (en) * | 2006-06-07 | 2007-12-13 | Reddy Us Therapeutics, Inc. | Compositions and methods to enhance reverse cholesterol transport |
| AR062841A1 (es) | 2006-09-15 | 2008-12-10 | Schering Corp | Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos |
| JO2653B1 (en) * | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB |
| CN101821243B (zh) * | 2007-10-11 | 2013-05-08 | 中国科学院上海药物研究所 | 一类嘧啶取代苯丙酸衍生物及其作为ppar激动剂的用途 |
| EP2224803B1 (en) | 2007-11-21 | 2014-04-02 | Janssen Pharmaceutica N.V. | Spiropiperidines for use as tryptase inhibitors |
| HRP20171587T1 (hr) * | 2010-10-18 | 2017-12-01 | Cerenis Therapeutics Holding Sa | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola |
| BR112013009531A2 (pt) * | 2010-11-11 | 2016-07-19 | Redx Pharma Ltd | derivados de fármaco |
| SG11201506456VA (en) | 2013-03-15 | 2015-09-29 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
-
2011
- 2011-10-18 HR HRP20171587TT patent/HRP20171587T1/hr unknown
- 2011-10-18 ES ES11835025.5T patent/ES2646835T3/es active Active
- 2011-10-18 JP JP2013535018A patent/JP5856177B2/ja active Active
- 2011-10-18 WO PCT/US2011/056780 patent/WO2012054535A2/en not_active Ceased
- 2011-10-18 NZ NZ705731A patent/NZ705731A/en not_active IP Right Cessation
- 2011-10-18 CN CN201710166195.0A patent/CN107011359A/zh active Pending
- 2011-10-18 MX MX2013004265A patent/MX337179B/es active IP Right Grant
- 2011-10-18 NZ NZ621551A patent/NZ621551A/en not_active IP Right Cessation
- 2011-10-18 CA CA2813994A patent/CA2813994A1/en not_active Abandoned
- 2011-10-18 SG SG2013020078A patent/SG189019A1/en unknown
- 2011-10-18 NZ NZ728819A patent/NZ728819A/en not_active IP Right Cessation
- 2011-10-18 PH PH1/2013/500480A patent/PH12013500480B1/en unknown
- 2011-10-18 SG SG10201708237SA patent/SG10201708237SA/en unknown
- 2011-10-18 KR KR1020187002317A patent/KR20180014188A/ko not_active Abandoned
- 2011-10-18 PT PT118350255T patent/PT2629776T/pt unknown
- 2011-10-18 NO NO11835025A patent/NO2629776T3/no unknown
- 2011-10-18 PL PL11835025T patent/PL2629776T3/pl unknown
- 2011-10-18 CN CN201180061000.7A patent/CN103442714B/zh active Active
- 2011-10-18 LT LTEP11835025.5T patent/LT2629776T/lt unknown
- 2011-10-18 SM SM20170533T patent/SMT201700533T1/it unknown
- 2011-10-18 SG SG2014012850A patent/SG2014012850A/en unknown
- 2011-10-18 NZ NZ607928A patent/NZ607928A/en unknown
- 2011-10-18 KR KR1020137011634A patent/KR101823615B1/ko active Active
- 2011-10-18 HU HUE11835025A patent/HUE034637T2/en unknown
- 2011-10-18 EP EP17175212.4A patent/EP3241833A1/en not_active Withdrawn
- 2011-10-18 EP EP11835025.5A patent/EP2629776B1/en active Active
- 2011-10-18 CN CN201610534210.8A patent/CN106167483B/zh active Active
- 2011-10-18 DK DK11835025.5T patent/DK2629776T3/da active
- 2011-10-18 AU AU2011317152A patent/AU2011317152C1/en active Active
- 2011-10-18 SI SI201131327T patent/SI2629776T1/sl unknown
- 2011-10-18 NZ NZ718514A patent/NZ718514A/en unknown
- 2011-10-18 RS RS20171152A patent/RS56529B1/sr unknown
- 2011-10-18 US US13/276,238 patent/US8349833B2/en not_active Expired - Fee Related
- 2011-10-18 NZ NZ734152A patent/NZ734152A/en not_active IP Right Cessation
- 2011-10-18 SG SG10201604731SA patent/SG10201604731SA/en unknown
- 2011-10-18 RU RU2013122834/04A patent/RU2576402C2/ru active
- 2011-10-18 BR BR112013009485A patent/BR112013009485A2/pt not_active Application Discontinuation
-
2012
- 2012-11-09 US US13/673,799 patent/US9085585B2/en not_active Expired - Fee Related
-
2013
- 2013-03-11 ZA ZA2013/01827A patent/ZA201301827B/en unknown
- 2013-04-17 IL IL225785A patent/IL225785A/en active IP Right Grant
-
2014
- 2014-03-27 ZA ZA2014/02287A patent/ZA201402287B/en unknown
-
2015
- 2015-06-03 US US14/729,908 patent/US9713619B2/en not_active Expired - Fee Related
- 2015-12-10 JP JP2015241010A patent/JP6127120B2/ja active Active
-
2016
- 2016-06-08 JP JP2016114435A patent/JP6254222B2/ja active Active
- 2016-06-24 US US15/191,820 patent/US9757381B2/en active Active
- 2016-11-02 PH PH12016502175A patent/PH12016502175A1/en unknown
-
2017
- 2017-01-30 IL IL250367A patent/IL250367A0/en unknown
- 2017-04-10 JP JP2017077272A patent/JP2017128602A/ja active Pending
- 2017-06-22 PH PH12017501185A patent/PH12017501185A1/en unknown
- 2017-07-14 PH PH12017501294A patent/PH12017501294A1/en unknown
- 2017-08-21 US US15/681,944 patent/US10220040B2/en active Active
- 2017-11-03 CY CY20171101154T patent/CY1119547T1/el unknown
- 2017-11-29 JP JP2017228551A patent/JP2018058874A/ja not_active Ceased
-
2019
- 2019-03-04 US US16/291,335 patent/US20200061072A1/en not_active Abandoned
- 2019-04-28 IL IL26628919A patent/IL266289B/en not_active IP Right Cessation
- 2019-09-20 IL IL26948919A patent/IL269489A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013122834A (ru) | Соединения, композиции и способы, подходящие для мобилизации холестерина | |
| JP2014077003A5 (enExample) | ||
| JP2017507987A (ja) | Ｔｃｏ複合体および治療薬の送達のための方法 | |
| JP2011514379A (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP6698643B2 (ja) | 多発性硬化症の治療のための組成物及び方法 | |
| EA025421B1 (ru) | Лечение липодистрофии | |
| JP2016508956A (ja) | 局所疼痛の治療のための組成物と治療法 | |
| US20170312309A1 (en) | Intradialytic administration of sodium thiosulfate | |
| JP2020100623A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
| CN103304501B (zh) | 一类抗糖尿病化合物、其制备方法和用途 | |
| WO2018071549A1 (en) | Nanoparticles and uses thereof | |
| US20220265614A1 (en) | Treatment comprising fxr agonists | |
| EP3307323B1 (en) | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof | |
| JP5068253B2 (ja) | 心臓血管疾患の治療 | |
| CN103304500B (zh) | 新型抗糖尿病化合物、其制备方法和用途 | |
| WO2019124411A1 (ja) | 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物 | |
| WO2026011229A1 (en) | Novel therapy | |
| WO2016156912A1 (en) | Use of thia oxo compounds for lowering apo c3 | |
| CN106573063A (zh) | 用于治疗糖尿病的咖啡醇 | |
| EP3045169B1 (en) | Aqueous solution formulation, and manufacturing method for same | |
| CN101024653B (zh) | 双过氧钒钾盐配合物及制备方法、单晶培养 | |
| JP2021134211A5 (enExample) | ||
| CN103304498B (zh) | 一种抗糖尿病化合物、其制备方法和用途 | |
| CN103304504B (zh) | 一种抗糖尿病化合物、其制备方法和用途 | |
| WO2020160619A1 (en) | A glycation reducing composition and method of use thereof |